证券代码：688117 证券简称：圣诺生物 公告编号：2026-002 | | | 占公 司 2024 | | 占公司 2025 年前三 | | --- | --- | --- | --- | --- | | 拟中选产品 | 2024 年销售收 | 年度 | 2025年1-9月 | 季度营 | | | 入（元） | 营业 | 销售收入（元） | 业收入 | | | | 收入 | | 比例 | | | | 比例 | | （%） | | | | （%） | | | | 醋酸奥曲肽注射剂 1ml:0.1mg | 58,503,254.76 | 12.83 | 38,224,482.51 | 7.35 | | 醋酸阿托西班注射剂 0.9ml:6.75mg | 1,920,360.16 | 0.42 | 1,314,098.27 | 0.25 | | 醋酸阿托西班注射剂 | 102,391,236.06 | 22.45 | 77,990,534.41 | 14.99 | | 5ml:37.5mg | | | | | | 生长抑素注射剂 3mg | 20,666,126.39 | 4.53 | 20,569,313.05 ...

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement process for the first to eighth batches of drugs, marking a significant step in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has engaged in the new round of centralized procurement organized by the state, which is the first nationwide unified continuation of centralized procurement for chemical drugs [1] - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] Group 2: Market Impact - The centralized procurement will prioritize the use of selected drugs by medical institutions, ensuring the completion of the agreed procurement volume [1] - The selection in this procurement round reflects the stability and reliability of the company’s drug quality, which is expected to further expand the sales scale of the selected products and increase market share [1] - The implementation of the procurement contract is anticipated to positively impact the company's operational development and strengthen its competitiveness in the peptide pharmaceutical market [1]

圣诺生物公告，全资子公司成都圣诺生物制药有限公司参与了国家组织的第一批至第八批国家集采药品 新一轮接续采购工作，公司产品醋酸奥曲肽注射剂（第七批中选）、醋酸阿托西班注射剂（第八批中 选）、生长抑素注射剂（第八批中选）与公司新中选产品胸腺法新注射剂、依替巴肽注射剂共同拟中选 本次新一轮接续采购。 ...

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation of centralized procurement for chemical drugs [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the new round of continuation procurement organized by the state [1] - The continuation procurement includes the company’s products such as Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch) [1] Group 2: Market Impact - The selected products will be prioritized for use by medical institutions during the procurement period, ensuring the completion of the agreed procurement volume [1] - The selection in this continuation procurement reflects the stability and reliability of the company’s drug quality, which is expected to expand the sales scale of the selected products and increase market share [1] - This development is anticipated to strengthen the company’s competitiveness in the peptide pharmaceutical market and positively impact its operational growth [1]

Group 1 - The core viewpoint of the news is that Shengnuo Bio has shown significant financial growth, with a notable increase in revenue and net profit for the first nine months of 2025 [2] - As of January 29, Shengnuo Bio's stock price decreased by 0.46%, with a trading volume of 89.92 million yuan and a net financing purchase of 3.20 million yuan [1] - The company's financing balance is 464 million yuan, accounting for 7.53% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] Group 2 - Shengnuo Bio's revenue for the period from January to September 2025 reached 520 million yuan, representing a year-on-year growth of 53.96% [2] - The net profit attributable to the parent company for the same period was 127 million yuan, showing a substantial increase of 123.03% year-on-year [2] - The company has distributed a total of 87.14 million yuan in dividends since its A-share listing, with 63.14 million yuan distributed over the past three years [3]

Group 1 - The company formerly known as 财讯传媒集团有限公司 has officially changed its name to BFB Health Limited [1] - The Chinese stock abbreviation has been updated from "财讯传媒" to "BFB HEALTH" [1] - BFB HEALTH has signed a strategic cooperation agreement with A-share listed company 圣诺生物 to collaborate in the biomedicine sector [1]

A股 Market Updates - On January 15, multiple A-share companies released their performance forecasts for 2025, with many expecting significant profit increases. SAIC Motor Corporation anticipates a net profit growth of up to 558%, while companies like Shengnuo Biological and Zhenghai Magnetic Materials expect increases exceeding 200% [2] - Jiamei Packaging announced that its stock has triggered redemption clauses due to its closing price being above 130% of the conversion price for 15 out of the last 30 trading days [2] - ST Chengchang and Zhizhi New Materials announced their resumption of trading after completing investigations into recent abnormal stock price fluctuations [2] - ST Aowei reported that its stock closed at 0.99 CNY per share, warning that if it remains below 1 CNY for 20 consecutive trading days, it may face delisting from the Shenzhen Stock Exchange [2] Logistics and E-commerce - SF Holding and Jitu Express announced a strategic mutual shareholding agreement, involving an investment transaction amounting to nearly 8.3 billion HKD [3] - Ctrip is under investigation by the State Administration for Market Regulation, leading to a significant drop in its stock price, with a 6.49% decline on the day of the announcement and a further 20% drop the following day, resulting in a market value loss exceeding 100 billion CNY [3] Financial Data - In 2025, the total number of new A-share accounts reached 27.44 million, a 10% increase year-on-year, marking a three-year high, with total A-share investors exceeding 250 million [4] - The People's Bank of China reported that by the end of 2025, the social financing scale reached 442.12 trillion CNY, growing by 8.3% year-on-year, while the RMB loan balance was 271.91 trillion CNY, up 6.4% [5] - The China Securities Regulatory Commission approved an adjustment to the margin ratio for financing, increasing the minimum margin requirement from 80% to 100%, effective January 19, 2026 [5] Gold Reserves - As of the end of November 2025, non-U.S. countries' official gold reserves exceeded 900 million troy ounces, valued at approximately 3.82 trillion USD [6] Infrastructure and Technology - The State Grid Corporation announced that its fixed asset investment is expected to reach 4 trillion CNY during the 14th Five-Year Plan, a 40% increase from the previous plan [7] - Alibaba's Qianwen App has integrated with various Alibaba ecosystem services, launching over 400 AI functionalities to enhance user experience in daily tasks [7] - Shanghai's new action plan aims to implement L4 autonomous driving technology in various scenarios by 2027, targeting over 6 million passenger trips and 800,000 TEU in freight transport [7] Housing Policy - A joint announcement from the Ministry of Finance, State Taxation Administration, and Ministry of Housing and Urban-Rural Development extended personal income tax policies supporting housing purchases from January 1, 2026, to December 31, 2027 [8] Trade Performance - China's total foreign trade in 2025 reached 45.47 trillion CNY, a 3.8% increase, setting a historical record and maintaining its position as the world's largest goods trading nation [8]

Core Viewpoint - Shengnuo Biopharma (688117.SH) is experiencing explosive growth in its performance, with a projected net profit of 152 million to 190 million yuan for 2025, representing a year-on-year increase of 204.42% to 280.53% [1][2] Financial Performance - Shengnuo Biopharma's revenue for 2022 was 396 million yuan, with a net profit of 64.48 million yuan. In 2023, revenue increased to 435 million yuan and net profit to 70.34 million yuan. In 2024, revenue reached 456 million yuan, while net profit slightly declined to 50.02 million yuan, setting the stage for the anticipated growth in 2025 [2] - For 2025, the company expects a significant leap in performance, with net profit projected between 152 million and 190 million yuan, and a non-recurring net profit forecasted between 149 million and 186 million yuan, indicating substantial growth compared to previous years [2] Business Growth Drivers - The core drivers of Shengnuo Biopharma's explosive growth include the rapid expansion of its peptide raw material business and simultaneous market development both domestically and internationally [2] - The company has successfully established a complete industrial chain platform covering peptide raw materials, formulation products, and innovative drug CDMO services over its 20 years of operation [2] Revenue Structure - Shengnuo Biopharma's revenue structure is primarily driven by raw materials and intermediates, with raw materials accounting for 56% of total revenue in the first half of 2025, showing a significant year-on-year growth of 232% [3] - The demand for GLP-1 raw materials has surged globally, driven by the penetration of original drug products in diabetes and obesity treatment, allowing Shengnuo to capitalize on this industry trend [3] Research and Development - The company has steadily increased its R&D investment over the years, with total R&D expenditure reaching 149 million yuan over the past five years, indicating a commitment to enhancing its core technologies and product pipeline [4] - Shengnuo Biopharma has provided peptide innovation drug research and custom production services to over 40 new drug development companies, with several projects at critical clinical trial stages [5] Asset Growth - Shengnuo Biopharma's total assets reached 19.09 billion yuan by the end of the third quarter of 2025, marking a 24.93% year-on-year increase and surpassing the 19 billion yuan milestone [5]

Core Viewpoint - The article highlights the exceptional performance of Shengnuo Biopharmaceuticals, which is expected to achieve a net profit of 152 million to 190 million yuan in 2025, marking a year-on-year increase of 204.42% to 280.53% [6]. Group 1: Company Performance - Shengnuo Biopharmaceuticals' projected net profit for 2025 is significantly higher than market expectations, with a forecasted increase of 1.02 billion to 1.40 billion yuan compared to the previous year [6]. - In contrast, the company's performance in 2024 showed a mere 4.84% revenue growth to 456 million yuan, with a net profit decline of 28.88% to 50.02 million yuan due to pricing pressures and increased R&D investments [6]. - The surge in 2025 is attributed to the overseas demand for GLP-1 raw materials, particularly for drugs like semaglutide and tirzepatide, which has led to a 232.3% increase in raw material revenue [8]. Group 2: Industry Dynamics - The global market for GLP-1 drugs is expanding rapidly, with predictions that the annual demand for GLP-1 raw materials could reach 50 tons by 2030 [9]. - The expiration of key patents for semaglutide in 2026 is expected to trigger a surge in the development and approval of generic and modified drugs, further increasing demand for raw materials [9]. - Shengnuo Biopharmaceuticals is positioned competitively in the domestic market, with an expected total production capacity of approximately 1.25 tons of peptide raw materials by the end of 2025 [8]. Group 3: Future Outlook - The growth logic for GLP-1 raw materials is anticipated to continue, with a tight supply-demand balance expected to persist in the short term [9]. - The industry is entering a phase of capacity competition, with several companies accelerating production, which may lead to price competition and margin pressure [9]. - Shengnuo Biopharmaceuticals' success in 2025 is seen as a result of strategically capitalizing on the global demand for GLP-1 raw materials, rather than a mere short-term luck [9].

Market Performance - The pharmaceutical sector experienced a decline of -1.18% on January 15, 2025, underperforming the CSI 300 index by 1.38 percentage points, ranking 25th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, other biological products (-0.04%), hospitals (-0.75%), and medical consumables (-0.77%) performed relatively well, while pharmaceutical distribution (-2.57%), medical devices (-2.51%), and offline pharmacies (-2.11%) lagged behind [1] - Top three gainers included Shanhe Pharmaceutical (+20.01%), Duori Pharmaceutical (+11.48%), and Yahong Pharmaceutical (+7.69%); top three losers were Sunflower (-20.00%), Hongbo Pharmaceutical (-20.00%), and Huaren Health (-19.99%) [1] Industry News - Ipsen announced that the FDA has granted breakthrough therapy designation for its investigational monoclonal antibody IPN60340, which is used in combination with Ven-Aza for the treatment of newly diagnosed acute myeloid leukemia (AML) patients who are not suitable for intensive therapy [2] - The designation is based on data from the Phase 1/2 EVICTION trial, showing that patients receiving the combination treatment had a nearly doubled complete remission rate compared to historical standard treatment data, particularly in subtypes that typically respond poorly to standard treatment [2] - IPN60340 targets BTN3A, a key immune regulatory molecule widely expressed in various cancers, promoting the recognition and elimination of tumor cells by γ9δ2 T cells [2] Company News - Saint Noble Bio (688117) announced an expected net profit attributable to shareholders of 152-190 million yuan for 2025, representing a year-on-year growth of 204.42%-280.53%, with a non-recurring net profit expected to be 149-186 million yuan, reflecting a growth of 226.07%-307.58% [3] - Yipinhong (300723) reported similar profit expectations for 2025, with a net profit forecast of 152-190 million yuan and a non-recurring net profit of 149-186 million yuan, both showing significant year-on-year growth [3] - Chutian Technology (300358) expects to achieve a net profit of 235-300 million yuan for 2025, marking a turnaround from losses in the previous year, with a non-recurring net profit forecast of 135-200 million yuan [3] - Ganli Pharmaceutical (603087) received approval from the Ethiopian National Food and Drug Administration for the registration of its insulin glargine injection and pre-filled pen, allowing for import and sale in Ethiopia [3]